Transcranial magnetic stimulation (TMS) has traveled a remarkable path from being a lab curiosity to becoming a mainstream, FDA-cleared treatment for mood and behavioral health conditions. Today, this noninvasive treatment—developed over four decades of research, engineering, and clinical trials—is widely available. By understanding the history of TMS therapy, you can appreciate the forty years of research that have shaped safer protocols, smarter devices, and better outcomes.
Since the 1980s, TMS has developed rapidly, receiving its first FDA clearance in the 2000s. Let us look at the major milestones in the evolution of TMS treatment.
The story of TMS therapy begins in 1985, when Anthony Barker and colleagues in Sheffield demonstrated that a rapidly changing magnetic field could painlessly induce small electrical currents in the human cortex, allowing precise, noninvasive stimulation of the brain. Their work transformed an idea rooted in Faraday’s electromagnetic induction into a practical neurophysiology tool used for motor mapping and basic brain research.
During the 1990s, investigators began testing repetitive TMS (rTMS) protocols, delivering trains of pulses to modulate activity in neural networks involved in depression. By the early 2000s, controlled studies and meta-analyses suggested antidepressant potential, laying the groundwork for pivotal trials and regulatory review of TMS therapy in the United States.
A major milestone arrived in 2008, when the FDA cleared the first TMS device for use on adults with major depressive disorder who had not achieved adequate benefit from prior medications. This decision followed multisite randomized data showing clinically meaningful improvement with a favorable safety profile. This marked the therapy’s transition into routine psychiatric practice.
As clinical adoption grew, researchers refined dosing, targets, and coil designs. Two advances stand out. First, the FDA permitted marketing of deep TMS for obsessive-compulsive disorder in 2018. Second, in that same year, the FDA cleared an intermittent theta-burst stimulation (iTBS) protocol—an ultra-brief treatment, broadening options for clinics and patients with busy schedules.
The 2020s brought additional milestones. Deep TMS treatment received FDA clearance as an aid for short-term smoking cessation, reflecting the field’s expansion beyond mood disorders into addiction neuroscience. More recently, clearances have extended to adolescent and young-adult populations, signaling growing confidence in both safety and applicability across age groups.
Decades of research and regulatory milestones have moved TMS therapy from academic labs to everyday clinical care. Our experienced team at The Holiner Psychiatric Group turns that progress into a clear, accessible TMS experience: a personalized consultation, individualized motor-threshold mapping, and a scheduled series of outpatient sessions, after which you can typically return to normal activities right away. Our team tailors coil placement, settings, and pacing to your goals and medical history. For today’s patients, this arc of innovation in the TMS field means evidence-based treatment options, multiple protocol choices, and a strong safety record, all delivered close to home.
At The Holiner Psychiatric Group, we are ready to help you explore whether TMS therapy is the right next step for your mental health. Our team can answer your questions on the history of TMS therapy, and we will walk you through every stage of the therapy process—from evaluation to treatment planning—so you can move forward with confidence. Call us today to schedule your TMS consultation and start your path toward lasting relief.